All In Biotech

Drug Trial Radar · NCT02120456

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Last checked: Nov 20, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

224

Actual

Start

May 2014

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Apr 22, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part 1: To identify Maximum Tolerated Dose (MTD) levels of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate the efficacy of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle

Conditions

  • Actinic Keratosis

Interventions

  • LEO 43204Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Participants Experiencing Dose Limiting Toxicity (DLT) Based on Local Skin Responses (LSRs)Time frame: From Day 1 up to and including Day 8
  2. Part 2: Percent Reduction From Baseline in Actinic Keratosis (AK) CountTime frame: From baseline to Week 8

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Omni Dermatology

    Phoenix, Arizona

  • Torrance Clinical Research Institute Inc.

    Lomita, California

  • Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.

    San Diego, California

  • Dermatology Associates and Research

    Coral Gables, Florida

  • Leavitt Medical Associates of Florida

    Ormond Beach, Florida

  • Deaconess Clinic, Inc.

    Evansville, Indiana

  • Hudson Dermatology, LLC

    Evansville, Indiana

  • Indiana Clinical Trials Center

    Plainfield, Indiana

  • DermAssociates, PC

    Rockville, Maryland

  • Great Lakes Research Group, Inc.

    Bay City, Michigan

  • The Dermatology Group, P.C.

    Verona, New Jersey

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Pflugerville Dermatology Clinical Research Center, Inc.

    Pflugerville, Texas

  • Kirk Barber Research

    Calgary, Alberta, Canada

  • Enverus Medical

    Surrey, British Columbia, Canada

  • Skin Care Centre

    Vancouver, British Columbia, Canada

  • Winnipeg Clinic Dermatology Research

    Winnipeg, Manitoba, Canada

  • UltraNova Skincare

    Barrie, Ontario, Canada

  • Dermatrials Research Incorporated

    Hamilton, Ontario, Canada

  • The Guenther Dermatology Research Centre

    London, Ontario, Canada

  • SKiN Centre for Dermatology

    Peterborough, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.